Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid
[...]targeting stromal signalling pathways such as sonic hedgehog signalling has also shown promising preclinical effects, and the results of ongoing clinical trials are eagerly awaited. [...]other cellular and acellular stromal components should be explored as further potential targets, among them...
Gespeichert in:
| Veröffentlicht in: | Gut 2012-10, Vol.61 (10), p.1377-1379 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1379 |
|---|---|
| container_issue | 10 |
| container_start_page | 1377 |
| container_title | Gut |
| container_volume | 61 |
| creator | Michl, Patrick Gress, Thomas M |
| description | [...]targeting stromal signalling pathways such as sonic hedgehog signalling has also shown promising preclinical effects, and the results of ongoing clinical trials are eagerly awaited. [...]other cellular and acellular stromal components should be explored as further potential targets, among them pancreatic stellate cells and activated stromal fibroblasts as major sources of the pancreatic stroma, as well as inflammatory cells, such as tumour-associated macrophages and other immune cells, 11 12 that are also involved in modulating tumour vasculature and matrix deposition. 13 Furthermore, stroma-related signalling pathways active in these cell types, such as the transforming growth factor β pathway, are promising candidates. |
| doi_str_mv | 10.1136/gutjnl-2012-302604 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1753477532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1039039142</sourcerecordid><originalsourceid>FETCH-LOGICAL-b506t-ddd3199d67484252063bb59639943e90676e54b4e89d9413424d5b60e8e883263</originalsourceid><addsrcrecordid>eNqNkUuLFDEUhYMoTs_oH3AhBW7clOb9cCc9jg4M42aUwU1IKre7q61Hm6QG-9-bosYR3CiEm1zudw65HIReEPyGECbfbqe8H7qaYkJrhqnE_BFaES51zajWj9EKY6Jqobg5Qacp7THGWhvyFJ1QKiXhRq5Qe9kf4njXDtsqxKkU6No7iMcqj9XBDU0El9umasoT4rvKl77ZzXTeQZVyHHvXVZsx5ggpVb7oXNxCnond0XVTHIcid00bnqEnG9cleH5_n6EvFx9u1p_qq88fL9fvr2ovsMx1CIERY4JUXHMqKJbMe2EkM4YzMFgqCYJ7DtoEwwnjlAfhJQYNWjMq2Rl6vfiWvX5MkLLt29RA17kBxilZogTjqhT6bxQzUw7hM_rqL3Q_TnEoixRDZTiVQvNC0YVq4phShI09xLZ38Vis7JyZXTKzc2Z2yayIXt5bT76H8CD5HVIB6gVoU4afD3MXv1upmBL2-uvafrs919fnt9Le_OF9v_-fD_wCcxqwDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779426584</pqid></control><display><type>article</type><title>Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Michl, Patrick ; Gress, Thomas M</creator><creatorcontrib>Michl, Patrick ; Gress, Thomas M</creatorcontrib><description>[...]targeting stromal signalling pathways such as sonic hedgehog signalling has also shown promising preclinical effects, and the results of ongoing clinical trials are eagerly awaited. [...]other cellular and acellular stromal components should be explored as further potential targets, among them pancreatic stellate cells and activated stromal fibroblasts as major sources of the pancreatic stroma, as well as inflammatory cells, such as tumour-associated macrophages and other immune cells, 11 12 that are also involved in modulating tumour vasculature and matrix deposition. 13 Furthermore, stroma-related signalling pathways active in these cell types, such as the transforming growth factor β pathway, are promising candidates.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gutjnl-2012-302604</identifier><identifier>PMID: 22661496</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject><![CDATA[Animals ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - therapeutic use ; Biomarkers, Tumor - metabolism ; Cancer ; carcinogenesis ; Cell Adhesion Molecules - administration & dosage ; Cell Adhesion Molecules - pharmacology ; cell migration ; Clinical trials ; Cytotoxicity ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Drug Delivery Systems ; Drug dosages ; Drug resistance ; Drug Resistance, Neoplasm - drug effects ; Drug Resistance, Neoplasm - physiology ; endoscopy ; Extracellular matrix ; Fibroblasts ; gastrointestinal cancer ; gene expression ; Humans ; Hyaluronic Acid - metabolism ; Hyaluronoglucosaminidase - administration & dosage ; Hyaluronoglucosaminidase - pharmacology ; Medical prognosis ; Metastasis ; Mice ; Mortality ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - metabolism ; pancreatic tumours ; pancreatitis ; Permeability ; Pharmaceutical industry ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - pharmacology ; Studies ; Tumors ; Vascular endothelial growth factor]]></subject><ispartof>Gut, 2012-10, Vol.61 (10), p.1377-1379</ispartof><rights>2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2012 (c) 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b506t-ddd3199d67484252063bb59639943e90676e54b4e89d9413424d5b60e8e883263</citedby><cites>FETCH-LOGICAL-b506t-ddd3199d67484252063bb59639943e90676e54b4e89d9413424d5b60e8e883263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://gut.bmj.com/content/61/10/1377.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://gut.bmj.com/content/61/10/1377.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3182,23551,27903,27904,77347,77378</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22661496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Michl, Patrick</creatorcontrib><creatorcontrib>Gress, Thomas M</creatorcontrib><title>Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid</title><title>Gut</title><addtitle>Gut</addtitle><description>[...]targeting stromal signalling pathways such as sonic hedgehog signalling has also shown promising preclinical effects, and the results of ongoing clinical trials are eagerly awaited. [...]other cellular and acellular stromal components should be explored as further potential targets, among them pancreatic stellate cells and activated stromal fibroblasts as major sources of the pancreatic stroma, as well as inflammatory cells, such as tumour-associated macrophages and other immune cells, 11 12 that are also involved in modulating tumour vasculature and matrix deposition. 13 Furthermore, stroma-related signalling pathways active in these cell types, such as the transforming growth factor β pathway, are promising candidates.</description><subject>Animals</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>carcinogenesis</subject><subject>Cell Adhesion Molecules - administration & dosage</subject><subject>Cell Adhesion Molecules - pharmacology</subject><subject>cell migration</subject><subject>Clinical trials</subject><subject>Cytotoxicity</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Drug Delivery Systems</subject><subject>Drug dosages</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Drug Resistance, Neoplasm - physiology</subject><subject>endoscopy</subject><subject>Extracellular matrix</subject><subject>Fibroblasts</subject><subject>gastrointestinal cancer</subject><subject>gene expression</subject><subject>Humans</subject><subject>Hyaluronic Acid - metabolism</subject><subject>Hyaluronoglucosaminidase - administration & dosage</subject><subject>Hyaluronoglucosaminidase - pharmacology</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Mortality</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>pancreatic tumours</subject><subject>pancreatitis</subject><subject>Permeability</subject><subject>Pharmaceutical industry</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Studies</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkUuLFDEUhYMoTs_oH3AhBW7clOb9cCc9jg4M42aUwU1IKre7q61Hm6QG-9-bosYR3CiEm1zudw65HIReEPyGECbfbqe8H7qaYkJrhqnE_BFaES51zajWj9EKY6Jqobg5Qacp7THGWhvyFJ1QKiXhRq5Qe9kf4njXDtsqxKkU6No7iMcqj9XBDU0El9umasoT4rvKl77ZzXTeQZVyHHvXVZsx5ggpVb7oXNxCnond0XVTHIcid00bnqEnG9cleH5_n6EvFx9u1p_qq88fL9fvr2ovsMx1CIERY4JUXHMqKJbMe2EkM4YzMFgqCYJ7DtoEwwnjlAfhJQYNWjMq2Rl6vfiWvX5MkLLt29RA17kBxilZogTjqhT6bxQzUw7hM_rqL3Q_TnEoixRDZTiVQvNC0YVq4phShI09xLZ38Vis7JyZXTKzc2Z2yayIXt5bT76H8CD5HVIB6gVoU4afD3MXv1upmBL2-uvafrs919fnt9Le_OF9v_-fD_wCcxqwDA</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Michl, Patrick</creator><creator>Gress, Thomas M</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20121001</creationdate><title>Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid</title><author>Michl, Patrick ; Gress, Thomas M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b506t-ddd3199d67484252063bb59639943e90676e54b4e89d9413424d5b60e8e883263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>carcinogenesis</topic><topic>Cell Adhesion Molecules - administration & dosage</topic><topic>Cell Adhesion Molecules - pharmacology</topic><topic>cell migration</topic><topic>Clinical trials</topic><topic>Cytotoxicity</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Drug Delivery Systems</topic><topic>Drug dosages</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Drug Resistance, Neoplasm - physiology</topic><topic>endoscopy</topic><topic>Extracellular matrix</topic><topic>Fibroblasts</topic><topic>gastrointestinal cancer</topic><topic>gene expression</topic><topic>Humans</topic><topic>Hyaluronic Acid - metabolism</topic><topic>Hyaluronoglucosaminidase - administration & dosage</topic><topic>Hyaluronoglucosaminidase - pharmacology</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Mortality</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>pancreatic tumours</topic><topic>pancreatitis</topic><topic>Permeability</topic><topic>Pharmaceutical industry</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Studies</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michl, Patrick</creatorcontrib><creatorcontrib>Gress, Thomas M</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michl, Patrick</au><au>Gress, Thomas M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>61</volume><issue>10</issue><spage>1377</spage><epage>1379</epage><pages>1377-1379</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><coden>GUTTAK</coden><abstract>[...]targeting stromal signalling pathways such as sonic hedgehog signalling has also shown promising preclinical effects, and the results of ongoing clinical trials are eagerly awaited. [...]other cellular and acellular stromal components should be explored as further potential targets, among them pancreatic stellate cells and activated stromal fibroblasts as major sources of the pancreatic stroma, as well as inflammatory cells, such as tumour-associated macrophages and other immune cells, 11 12 that are also involved in modulating tumour vasculature and matrix deposition. 13 Furthermore, stroma-related signalling pathways active in these cell types, such as the transforming growth factor β pathway, are promising candidates.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><pmid>22661496</pmid><doi>10.1136/gutjnl-2012-302604</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0017-5749 |
| ispartof | Gut, 2012-10, Vol.61 (10), p.1377-1379 |
| issn | 0017-5749 1468-3288 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1753477532 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | Animals Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - therapeutic use Biomarkers, Tumor - metabolism Cancer carcinogenesis Cell Adhesion Molecules - administration & dosage Cell Adhesion Molecules - pharmacology cell migration Clinical trials Cytotoxicity Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug Delivery Systems Drug dosages Drug resistance Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - physiology endoscopy Extracellular matrix Fibroblasts gastrointestinal cancer gene expression Humans Hyaluronic Acid - metabolism Hyaluronoglucosaminidase - administration & dosage Hyaluronoglucosaminidase - pharmacology Medical prognosis Metastasis Mice Mortality Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism pancreatic tumours pancreatitis Permeability Pharmaceutical industry Recombinant Proteins - administration & dosage Recombinant Proteins - pharmacology Studies Tumors Vascular endothelial growth factor |
| title | Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A32%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improving%20drug%20delivery%20to%20pancreatic%20cancer:%20breaching%20the%20stromal%20fortress%20by%20targeting%20hyaluronic%20acid&rft.jtitle=Gut&rft.au=Michl,%20Patrick&rft.date=2012-10-01&rft.volume=61&rft.issue=10&rft.spage=1377&rft.epage=1379&rft.pages=1377-1379&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gutjnl-2012-302604&rft_dat=%3Cproquest_cross%3E1039039142%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779426584&rft_id=info:pmid/22661496&rfr_iscdi=true |